500303-81-1

Basic information

• Product Name: ethyl [[4-[2-(5-cyano-2-methoxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yl]amino]acetate
• Synonyms: ethyl [[4-[2-(5-cyano-2-methoxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yl]amino]acetate
• CAS NO: 500303-81-1
• Molecular Weight: 571.675
• Mol File: 500303-81-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl [[4-[2-(5-cyano-2-methoxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yl]amino]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl [[4-[2-(5-cyano-2-methoxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yl]amino]acetate(500303-81-1)
• EPA Substance Registry System: ethyl [[4-[2-(5-cyano-2-methoxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yl]amino]acetate(500303-81-1)

Safety Data

• Hazardous Substances Data: 500303-81-1(Hazardous Substances Data)

Upstream product

• 19614-16-5 2-bromo-1-(methylsulfanyl)benzene 
• 500303-75-3 N-[2-(2-amino-4-bromophenyl)ethyl]-5-cyano-2-methoxybenzenesulfonamide 
• 33951-33-6 1-bromo-2-(methylsulfonyl)benzene 
• 12150-46-8 1,1'-bis(diphenylphosphino)ferrocene 
• 500303-77-5 ethyl [5-bromo-2-[2-(5-cyano-2-methoxybenzenesulfonylamino)-ethyl]phenylamino]acetate 
• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

Orally active factor Xa inhibitors: Investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy

A series of novel and potent 3-amidinophenylsulfonamide derivatives of factor Xa inhibitors were designed and synthesized using an amidoxime prodrug strategy. We focused on systemic clearance of parent compounds in rats, and performed in vivo pharmacokinetic screening. Incorporation of a carboxymethoxy group markedly improved systemic clearance (compound 43), and the related amidoxime 44 showed sufficient prodrug conversion. Compound 45, the double prodrug of 43, exhibited practicable bioavailability after oral administration in rats. Among the various compounds under investigation, KFA-1982 was selected for clinical development.